Search for Companies, Tipsters or Sources…
Companies
Tipsters
Brokers
Sources
Or view the latest share tips
Company Results
Tipster results
Broker results
Sources results
Fund Manager results
Tips from these results
Recent Share tips:
- Buy HSBC Holdings (HSBA) by Simon Watkins in The Motley Fool
- Buy SSE (SSE) by Berenberg
- Buy Town Centre Securities (TOWN) by Russ Mould in The Telegraph - Questor
- Hold GSK (GSK) by Russ Mould in The Telegraph - Questor
- Buy Unilever (ULVR) by Mark Rogers in The Motley Fool
- Buy Greencoat UK Wind (UKW) by Royston Wild in The Motley Fool
- Buy BlackRock Greater Europe Inv Trust (BRGE) by Lauren Almeida in The Times - Tempus
- Hold Tristel (TSTL) by Kevin Godbold in The Motley Fool
- Buy Golden Prospect Precious Metals Ltd. (GPM) by Nigel Somerville in ShareProphets
- Avoid SIG (SHI) by Steve Moore in ShareProphets
- Avoid Fonix (FNX) by Steve Moore in ShareProphets
- Watch British Land Company (BLND) by Jon Smith in The Motley Fool
- Sell React Group (REAT) by Hot Stock Rockets in ShareProphets
- Buy AstraZeneca (AZN) by Simon Watkins in The Motley Fool
- Buy Experian (EXPN) by UBS
- Neutral Rentokil Initial (RTO) by UBS
- Neutral Ashtead Group (AHT) by UBS
- Buy DCC (CDI) (DCC) by UBS
- Neutral RS Group (RS1) by UBS
- Buy Yellow Cake (YCA) by Citi
Physiomics (PYC) Share Price
Health Care Sector
NOTE: This is based on 17 open tips for Physiomics (PYC)
| Latest Bid : 0.65p | Latest Ask : 0.70p |
| High Today : 0.68p | Low Today : 0.65p |
| This Years High : 2.00p | This Years Low : 0.62p |
| Volume : 187 | MKT Cap : £1.42M |
| Trading Velocity : Premium Only | Activity Score : Premium Only |
| Consensus Score : Premium Only | Momentum Score : Premium Only |
Stock Splits and Consolidations
19/12/2016 – Stock Consolidation 100.000:1.000
Physiomics (PYC) Overview
Physiomics' vision is to transform oncology drug development. We believe in innovation, collaboration, diversity and inclusion and we aim to bring out the best in each other, in order to help our partners develop great cancer drugs and to apply them optimally in real-world settings.Physiomics (PYC) Latest Tips
| Type | Tipster | SectorScore | Start date | Performance |
|---|---|---|---|---|
| Avoid | Steve Moore | Premium Only | 2024-09-27 09:25:00 27/09/2024 | -16.67% |
| Avoid | Steve Moore | Premium Only | 2024-07-03 12:05:00 03/07/2024 | -16.67% |
| Avoid | Steve Moore | Premium Only | 2024-05-03 14:25:00 03/05/2024 | 41.67% |
| Sell | Tom Winnifrith | Premium Only | 2024-03-07 16:20:00 07/03/2024 | 46.15% |
| Avoid | Steve Moore | Premium Only | 2023-11-10 13:55:00 10/11/2023 | 53.33% |
Physiomics (PYC) Active Short Positions
| Fund Manager | Position | Date | ||
|---|---|---|---|---|
| No active short positions | ||||
| Latest Bid : 0.65p | Latest Ask : 0.70p |
| High Today : 0.68p | Low Today : 0.65p |
| This Years High : 2.00p | This Years Low : 0.62p |
| Volume : 187 | MKT Cap : £1.42M |
Physiomics Overview
Physiomics' vision is to transform oncology drug development. We believe in innovation, collaboration, diversity and inclusion and we aim to bring out the best in each other, in order to help our partners develop great cancer drugs and to apply them optimally in real-world settings.NOTE: This description is in part generated by ChatGPT and not an endorsement by or the opinion of Stockomendation Ltd.
Latest Physiomics Tips
| Type | Tipster | SectorScore | Start date | Performance |
|---|---|---|---|---|
| Avoid | Steve Moore | Premium Only | 2024-09-27 09:25:00 27/09/2024 | -16.67% |
| Avoid | Steve Moore | Premium Only | 2024-07-03 12:05:00 03/07/2024 | -16.67% |
| Avoid | Steve Moore | Premium Only | 2024-05-03 14:25:00 03/05/2024 | 41.67% |
| Sell | Tom Winnifrith | Premium Only | 2024-03-07 16:20:00 07/03/2024 | 46.15% |
| Avoid | Steve Moore | Premium Only | 2023-11-10 13:55:00 10/11/2023 | 53.33% |
Stock Splits and Consolidations
19/12/2016 – Stock Consolidation 100.000:1.000